Cargando…
A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab
Immune checkpoint inhibitors can be potentially cardiotoxic. It has not been frequently reported in the literature. Cardiomyopathy with these agents can have early onset and may start with non-specific symptoms like fatigue, weakness before presenting with obvious features of acute heart failure. Ra...
Autores principales: | Sharma, Munish, Suero-Abreu, Giselle A., Kim, Bernard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469913/ https://www.ncbi.nlm.nih.gov/pubmed/31019642 http://dx.doi.org/10.14740/cr838 |
Ejemplares similares
-
Role of Phosphodiesterase-5 Inhibitors in Acute Right Ventricular Failure Due to Pulmonary Embolism
por: Sharma, Munish, et al.
Publicado: (2019) -
Atherosclerosis With Immune Checkpoint Inhibitor Therapy: Evidence, Diagnosis, and Management: JACC: CardioOncology State-of-the-Art Review
por: Suero-Abreu, Giselle Alexandra, et al.
Publicado: (2022) -
The Tale of a Double-Edged Sword: Protecting the Heart from Metastatic Melanoma Tumor and its Treatment with Pembrolizumab
por: Suero-Abreu, Giselle A., et al.
Publicado: (2019) -
Biomarkers for immune checkpoint blockers
por: Wienand, Kirsty, et al.
Publicado: (2018) -
Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab
por: Zand Irani, Anis, et al.
Publicado: (2023)